Study Objectives: Tolperisone is a centrally acting muscle relaxant being developed in the US as a treatment for acute and painful symptoms of neck and low back muscle spasms. This study explores the impact of tolperisone on driving simulation endpoints, sedation, and cognition compared to placebo (PBO) and cyclobenzaprine (CYC). The CYC half-life is long (>19 hours) and accumulated over the 3 days of the trial. Tolperisone has a Tmax of 1 hour, and a 2-to 3-hour half-life.
Methods: This was a 3-way, randomized, blinded, crossover study of tolperisone in 31 healthy volunteers. Treatment groups were 450 mg tolperisone administered 3-times a day (150 mg TID), 30 mg CYC (10 mg TID), and PBO (TID). Participants spent 3 days of 3 consecutive weeks in the research unit. Dosing occurred in the morning (AM) and at midday (PM) on Days 1-3 and at bedtime on Days 1 and 2. Subjects were administered a DSST followed by 100 km (60 minute) of simulated driving on Day 1 one hour after their midday dose (at drug Tmax), and the morning of Day 2 (pre-dosing) to assess next day residual effects. Tests were the morning of Day 3 (post-dose) to assess the drug at steady-state. Subjects returned to the clinic on Days 7 and 14 to repeat these procedures.
Results: For the primary endpoint of Standard Deviation of Lateral Position (SDLP) over 100-km of driving, tolperisone was no different than PBO, whereas CYC showed significant impairment (p¼<0.001).
The distribution of SDLP for PBO and tolperisone showed symmetry around zero, while CYC was markedly different; a subset of subjects had a level of impairment associated with increased crash risk, demonstrated by SDLP values above 4.4 cm (consistent with normative Blood Alcohol Concentration (BAC) levels of above 0.05%).
Secondary measures confirmed a lack of sedation for tolperisone relative to PBO: Digit Symbol Coding Day 1 p¼ 0.84, Day 2 p¼ 0.21, Day 3 p¼ 0.12; and Karolinska Sleepiness Scale: Day 1 p¼ 0.47, Day 2 p¼ 0.47, and Day 3 p¼ 0.49. Additional measures of driving indicated no impairment for tolperisone versus PBO.
Conclusions: Tolperisone 150 mg TID had no impact on various measures of driving, self-reported sleepiness, and cognition, in contrast to CYC 10 mg TID. Data confirms impairment in cognition and driving for healthy subjects taking CYC. Study Objectives: Pain management in the pediatric setting has been a widely discussed topic, especially with new Food and Drug Administration (FDA) recommendations regarding codeine and tramadol. Previous studies showed that the use of opioids increased in the adult and pediatric population. Use of opioids is not benign and is linked to misuse, abuse, addiction and overdoses. We aimed to look at the use of narcotic and non-narcotic pain medications at a large pediatric hospital to discern if patterns of pain medications changed over time.
Methods: 58402 analgesic prescriptions of patients 0-21 years of age were analyzed from May 2012 to November 2016. Prescriptions from the emergency department as well as the inpatient setting were included. Demographic information, type of medication, prescriber type, insurance information and diagnosis were analyzed with multivariable analysis. A logistic regression model was fitted to examine the association of age, sex, primary diagnosis and the length of hospital stay with probability of opioid prescription.
Results: 36560 patients aged 0-21 years, (Mean: 10.5, Median: 11.0, SD: 7.42) received analgesic pain medications. 21847 patients were prescribed more than 1 analgesic. There was a male predominance in patients less than age of 15; however, in adolescents >16 years, females constituted 57.1% of patients. The relative frequency of opioid prescription was 29.3% for physicians, 27.8% for residents, 31.3% for nurse practitioners and 15.9% for physician assistants. There was a statistically significant difference between physicians and nurse practitioners (P<0.01) and also physicians and physician assistants' relative frequency of opioid prescription (P<0.001); however, the difference was not statistically significant in residents compared to physicians' prescription (P¼0.117). Data also showed a statistically significant reduction of opioid prescriptions (P<0.001) from 2012 to 2016 (Figure 1 ). According to the multivariable analysis age and length of hospital stay were directly associated with opioid prescription (P<0.05), adjusted for the other variables.
Conclusions: Data shows that there is a decrease in overall opioid prescriptions amongst pediatric patients. This may be secondary to recent recommendations by the FDA in regards to codeine and tramadol, which are considered "weaker" opioids. Not surprisingly, increased hospital stay led to more analgesic prescriptions. The higher opioid prescription rate among nurse practitioners needs
